Astrazeneca PLC Sponsored ADR (AZN.US)Two cancer drugs will undergo FDA expert panel judgment.

Recently, the FDA website announced that the Oncologic Drugs Advisory Committee (ODAC) meeting will be held on April 30, 2026 to discuss two marketing applications submitted by Astrazeneca PLC Sponsored ADR (AZN.US): Oral SERD drug Camizestrant combined with CDK4/6 inhibitors for the first-line treatment of locally advanced or metastatic HR+/HER2- breast cancer with ESR1 mutations AKT inhibitor Capivasertib combined with Abiraterone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) with PTEN defects. Camizestrant is the next-generation oral selective estrogen receptor degrader (SERD) developed by Astrazeneca PLC Sponsored ADR, and has been filed for marketing approval in the United States, Europe, and Japan. Capivasertib is a highly selective inhibitor of AKT1/2/3 developed by Astrazeneca PLC Sponsored ADR. Activation of the AKT signaling pathway, including changes in PIK3CA, AKT1, and PTEN, can occur in many patients with HR+/HER2- advanced breast cancer, but may also occur in patients without these genetic changes. The AKT signaling pathway is associated with the development of resistance to hormonal therapy.